Cord Blood News 10.20 May 24, 2018 | |
| |
TOP STORYSmall Hypoxia-Primed Mesenchymal Stem Cells Attenuate Graft-versus-Host Disease Investigators showed that small MSCs primed with hypoxia and calcium ions (SHC-MSCs) exhibit enhanced stemness and immunomodulatory functions for treating allogeneic conflicts. Compared with naïve cultured human umbilical cord blood-derived MSCs, SHC-MSCs were resistant to passage-dependent senescence mediated via the monocyte chemoattractant protein-1 and p53/p21 cascade and secreted large amounts of pro-angiogenic and immunomodulatory factors, resulting in suppression of T-cell proliferation. [Leukemia] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting Researchers identified critical parameters to reproducibly achieve high frequencies of RNA-guided and rAAV6-mediated homologous recombination at the β-globin locus in hematopoietic stem and progenitor cells. [Mol Ther Nucleic Acids] Full Article IL-37 Isoform D Downregulates Pro-Inflammatory Cytokines Expression in a Smad3-Dependent Manner Scientists showed that IL-37d possesses anti-inflammatory roles both in vitro and in vivo. IL-37d was expressed in peripheral blood mononuclear cells and umbilical cord-derived MSCs. [Cell Death Dis] Full Article Investigators performed reduced-intensity conditioning before umbilical cord blood transplantation in patients with interleukin-10 receptor-A deficiency. They enrolled 9 very early-onset inflammatory bowel disease patients with typical manifestations. [Inflamm Bowel Dis] Abstract Depletion of Endothelin Receptor B (EDNRB) mRNA in cord blood-derived CD34+ cells led to defective B cell differentiation, supporting a hypothesis that low EDNRB expression in T21 contributes to intrinsic lymphoid defects. [Sci Rep] Full Article Human mesenchymal stem cells derived from Wharton’s jelly (WJ-MSCs) were used for the treatment of the ischemic-compression model of spinal cord injury in rats. To assess the effectivity of the treatment, different dosages and repeated applications were compared. Significant recovery of functional outcome was observed in all of the treated groups except for the single application of the lowest number of cells. [Int J Mol Sci] Full Article | |
| |
REVIEWSFactors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape One of the most appealing attributes of umbilical cord blood (UCB) is that it can be banked for future use and hence provides an off-the-shelf solution for patients in urgent need of a transplantation. This has led to the establishment of publicly funded and private UCB banks, as seen by the rapid growth of the UCB industry in the early part of this century. However, from about 2010, the release of UCB units for treatment purposes plateaued and started to decrease year-on-year from 2013 to 2016. Researchers investigate the factors contributing to these changes. [Stem Cells Transl Med] Full Article Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSAbbVie announced that the Phase III iLLUMINATE trial met its primary endpoint of improvement in progression-free survival. The study evaluated IMBRUVICA® in combination with GAZYVA® in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma patients. [AbbVie] Press Release Trovagene, Inc. announced the completion of the first dose cohort in its Phase Ib/II clinical trial of PCM-075, a highly-selective polo-like kinase 1 inhibitor, in combination with LDAC, in acute myeloid leukemia. [Trovagene, Inc.] Press Release Seattle Cancer Care Alliance recently opened the Hematologic Malignancy Genetics Clinic, which provides personalized risk assessment and follow-up care for adult patients and family members who may be at increased risk for developing hematologic malignancies due to an underlying genetic cause. [Seattle Cancer Care Alliance (Newswise, Inc)] Press Release | |
| |
POLICY NEWSPlans for £100M Nobel Centre Blocked by Swedish Court A Swedish court has blocked the construction of a major new Nobel Centre in Stockholm intended as the future venue for the world’s most prestigious arts and science awards. [The Guardian] Editorial PM Will Pay to Have ‘Full Association’ with EU Research The Prime Minister made the strongest commitment yet to “fully associate” the UK with the EU’s £68bn research program post-Brexit. Theresa May said the UK would be willing to make “an appropriate contribution” and in return it would expect a “suitable level of influence”. [BBC News] Editorial Science Needs Clarity on Europe’s Data-Protection Law As a commendable European law on personal data comes into force, the research community must not let excessive caution about data sharing, however understandable, become the default position. [Nature News] Editorial
| |
EVENTSNEW 20th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Research Scholar – Hematologic Malignancies (Washington University School of Medicine) Postdoctoral Position – Leukemia (Oslo Universitetssykehus HF) Postdoctoral Fellow – B-Cell Lymphoma (University of Texas Health Science Center) Postdoctoral Fellow – Hematopoiesis and Leukemia (University of Pennsylvania) Research Fellow – Hematology, Blood Disorders and Stem Cell Biology (New York Blood Center) Postdoctoral Fellow – Molecular and Translational Cancer Biology (Thomas Jefferson University) Postdoctoral Position – Hematology (Yale Cancer Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|